Cholecalciferol supplementation in chronic kidney disease: Restoration of vitamin D status and impact on parathyroid hormone

Annals of Nutrition and Metabolism

Volumn 61, Issue 1, 2012, Pages 74-82

  Garcia Lopes, Miriam G ^a   Pillar, Roberta ^a   Kamimura, Maria Ayako ^a   Rocha, Lillian A ^a   Canziani, Maria Eugênia F ^a   Carvalho, Aluzio B ^a   Cuppari, Lilian ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adiposity; Cholecalciferol; Chronic kidney disease; Parathyroid hormone; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; VITAMIN D;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; AGED; BODY COMPOSITION; BRAZIL; CALCIUM; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84864803163     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000339618     Document Type: Article

References (29)

1. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95.
2. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, Martins D, Adler SG, Norris KC: Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76: 977-983.
3. Cuppari L, Carvalho AB, Draibe SA: Vitamin D status of chronic kidney disease patients living in a sunny country. J Ren Nutr 2008; 18: 408-414.
4. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K: Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1144-1151.
5. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-510.
6. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR: Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007; 11: 315-321.
7. Shah N, Bernardini J, Piraino B: Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 2005; 25: 362-366.
8. Figuiredo-Dias V CL, Garcia-Lopes MG, Carvalho AB, Draibe SA, Kamimura MA: Risk factors for hypovitaminosis D in nondialyzed chronic kidney disease patients. J Ren Nutr 2012; 22: 4-11.
9. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003; 42:S1-S201.
10. KDIGO Clinical Practice Guideline For The Diagnosis, Evaluation, Prevention, And Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 76:S1-S130.
11. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ: Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50: 59-68.
12. Zisman AL, Hristova M, Ho LT, Sprague SM: Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27: 36-43.
13. Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V: Cholecalciferol (vitamin D 3 ) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008; 14: 10-17.
14. Rucker D, Tonelli M, Coles MG, Yoo S, Young K, McMahon AW: Vitamin D insufficiency and treatment with oral vitamin D 3 in northern-dwelling patients with chronic kidney disease. J Nephrol 2009; 22: 75-82.
15. Qunibi WY, Abdellatif A, Sankar S, Hamdan Z, Lin FY, Ingle J, Cadena A, Gelfond J, Kasinath B: Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate? Clin Nephrol 2010; 73: 276-285.
16. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996; 7: 198-207.
17. Vilarrasa N, Maravall J, Estepa A, Sanchez R, Masdevall C, Navarro MA, Alia P, Soler J, Gomez JM: Low 25-hydroxyvitamin D concentrations in obese women: their clinical significance and relationship with anthropometric and body composition variables. J Endocrinol Invest 2007; 30: 653-658.
18. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF: Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-693.
19. Lee P, Greenfield JR, Seibel MJ, Eisman JA, Center JR: Adequacy of vitamin D replacement in severe deficiency is dependent on body mass index. Am J Med 2009; 122: 1056-1060.
20. Blum M, Dallal GE, Dawson-Hughes B: Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults. J Am Coll Nutr 2008; 27: 274-279.
21. Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, Li K, Bassali R, Guo DH, Thomas J, Pierce GL, White J, Holick MF, Zhu H: A 16-week randomized clinical trial of 2000 international units daily vitamin D 3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab 2010; 95: 4584-4591.
22. Kawahara M, Iwasaki Y, Sakaguchi K, Taguchi T, Nishiyama M, Nigawara T, Tsugita M, Kambayashi M, Suda T, Hashimoto K: Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci 2008; 82: 677-683.
23. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ: 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006; 70: 654-659.
24. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE: Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131.
25. Van Driel M, Koedam M, Buurman CJ, Hewison M, Chiba H, Uitterlinden AG, Pols HA, van Leeuwen JP: Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 2006; 20: 2417-2419.
26. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
27. Titan SM, Zatz R, Graciolli FG, Dos Reis LM, Barros RT, Jorgetti V, Moyses RM: FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011; 6: 241-247.
28. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH: FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25: 3983-3989.
29. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.